Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively

Vaccine

Volumn 28, Issue 7, 2010, Pages 1881-1886

  Meddeb Garnaoui, A ^a   Toumi, A ^a   Ghelis, H ^a   Mahjoub, M ^a   Louzir, H ^a   Chenik, M ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Histone; Human immunogenicity; Leishmania

Indexed keywords

GAMMA INTERFERON; HISTONE H2B; INTERLEUKIN 10; LEISHMANIA VACCINE; PROTOZOON ANTIBODY;

ADOLESCENT; ADULT; AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN LEISHMANIASIS; TH1 CELL; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; HISTONES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFANT; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MIDDLE AGED; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TH1 CELLS; YOUNG ADULT;

EID: 75249092706     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.075     Document Type: Article

References (42)

1. WHO Leishmaniasis: background information. Available at: http://www.whoint/leishmaniasis/en/2009.
2. Salah A.B., Kamarianakis Y., Chlif S., Alaya N.B., and Prastacos P. Zoonotic cutaneous leishmaniasis in central Tunisia: spatio temporal dynamics. Int J Epidemiol 36 October (5) (2007) 991-1000
3. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351 May (9115) (1998) 1540-1543
4. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180 August (2) (1999) 564-567
5. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356 November (9241) (2000) 1565-1569
6. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 November (11) (2002) 845-858
7. Mansueto P., Vitale G., Di Lorenzo G., Rini G.B., Mansueto S., and Cillari E. Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 20 July-September (3) (2007) 435-445
8. Kharazmi A., Kemp K., Ismail A., Gasim S., Gaafar A., Kurtzhals J.A., et al. T-cell response in human leishmaniasis. Immunol Lett 65 January (1-2) (1999) 105-108
9. Ajdary S., Alimohammadian M.H., Eslami M.B., Kemp K., and Kharazmi A. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68 April (4) (2000) 1760-1764
10. Carvalho E.M., Correia Filho D., Bacellar O., Almeida R.P., Lessa H., and Rocha H. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 53 September (3) (1995) 273-277
11. Sassi A., Louzir H., Ben Salah A., Mokni M., Ben Osman A., and Dellagi K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol 116 April (1) (1999) 127-132
12. Probst P., Stromberg E., Ghalib H.W., Mozel M., Badaro R., Reed S.G., et al. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 166 January (1) (2001) 498-505
13. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y.A., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69 June (6) (2001) 4103-4108
14. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 195 June (12) (2002) 1565-1573
15. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 August (8) (2002) 4215-4225
16. Herwaldt B.L. Leishmaniasis. Lancet 354 October (9185) (1999) 1191-1199
17. Singh S., and Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med 49 January-March (1) (2003) 55-60
18. Sundar S., and Benjamin B. Diagnosis and treatment of Indian visceral leishmaniasis. J Assoc Physicians India February (51) (2003) 195-201
19. Pedras M.J., de Gouvea Viana L., de Oliveira E.J., and Rabello A. Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 102 February (2) (2008) 172-178
20. Chappuis F., Rijal S., Jha U.K., Desjeux P., Karki B.M., Koirala S., et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop Med Int Health 11 January (1) (2006) 31-40
21. Schallig H.D., Schoone G.J., Kroon C.C., Hailu A., Chappuis F., and Veeken H. Development and application of 'simple' diagnostic tools for visceral leishmaniasis. Med Microbiol Immunol 190 November (1-2) (2001) 69-71
22. Maalej I.A., Chenik M., Louzir H., Ben Salah A., Bahloul C., Amri F., et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg 68 March (3) (2003) 312-320
23. Badaro R., Benson D., Eulalio M.C., Freire M., Cunha S., Netto E.M., et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 173 March (3) (1996) 758-761
24. Zijlstra E.E., Nur Y., Desjeux P., Khalil E.A., El-Hassan A.M., and Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health 6 February (2) (2001) 108-113
25. Mandal J., Khurana S., Dubey M.L., Bhatia P., Varma N., and Malla N. Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 79 July (1) (2008) 76-78
26. Soto M., Requena J.M., Quijada L., Gomez L.C., Guzman F., Patarroyo M.E., et al. Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Clin Exp Immunol 106 December (3) (1996) 454-461
27. Soto M., Requena J.M., Quijada L., Perez M.J., Nieto C.G., Guzman F., et al. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin Exp Immunol 115 February (2) (1999) 342-349
28. Chenik M., Louzir H., Ksontini H., Dilou A., Abdmouleh I., and Dellagi K. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Vaccine 24 March (14) (2006) 2521-2529
29. Requena J.M., Alonso C., and Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today 16 June (6) (2000) 246-250
30. Montoya Y., Leon C., Talledo M., Nolasco O., Padilla C., Munoz-Najar U., et al. Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 91 November-December (6) (1997) 674-676
31. Soto M., Requena J.M., Quijada L., Garcia M., Guzman F., Patarroyo M.E., et al. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett 48 December (3) (1995) 209-214
32. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 68 October (10) (2000) 5595-5602
33. Iborra S., Soto M., Carrion J., Alonso C., and Requena J.M. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 22 September (29-30) (2004) 3865-3876
34. Carrion J., Folgueira C., and Alonso C. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Vaccine 26 February (9) (2008) 1155-1165
35. Von Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17 March-April (2) (2007) 115-122
36. Anderson C.F., Oukka M., Kuchroo V.J., and Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204 February (2) (2007) 285-297
37. Lakhal-Naouar I., Boussoffara T., Meddeb-Garnaoui A., Ben Achour-Chenik Y., Louzir H., and Chenik M. Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients. Clin Vaccine Immunol 16 June (6) (2009) 956-958
38. de Carvalho L.P., Soto M., Jeronimo S., Dondji B., Bacellar O., Luz V., et al. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect 5 January (1) (2003) 7-12
39. Nylen S., Maasho K., McMahon-Pratt D., and Akuffo H. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors. Scand J Immunol 59 March (3) (2004) 294-304
40. Azeredo-Coutinho R.B., Matos D.C., Armoa G.G., Maia R.M., Schubach A., Mayrink W., et al. Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization. Clin Exp Immunol 153 September (3) (2008) 369-375
41. Wallace G.R., Ball A.E., MacFarlane J., el Safi S.H., Miles M.A., and Kelly J.M. Mapping of a visceral leishmaniasis-specific immunodominant B-cell epitope of Leishmania donovani Hsp70. Infect Immun 60 July (7) (1992) 2688-2693
42. Soto M., Requena J.M., Quijada L., Guzman F., Patarroyo M.E., and Alonso C. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol Lett 48 November (1) (1995) 23-28